RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  World journal of urology

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00345-017-2145-yPMID 29204705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy

  2014cited by this paper
• Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases

  2013cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

  2010cited by this paper
• Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas

  2009cited by this paper
• Targeting the receptor activator of nuclear factor‐κB (RANK) ligand in prostate cancer bone metastases

  2008cited by this paper
• RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

  2008cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• RANKL-RANK signaling in osteoclastogenesis and bone disease.

  2006cited by this paper
• Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

  2006influential reference
• Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma.

  2005cited by this paper
• Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities

  2002cited by this paper
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002cited by this paper
• Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

  2001cited by this paper
• Osteoprotegerin and rank ligand expression in prostate cancer.

  2001cited by this paper
• Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

  2000cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

  1999cited by this paper
• Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

  1995cited by this paper
• Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein

  1995cited by this paper

• Thyroid C-Cell Biology and Oncogenic Transformation.

  2025cites this paper
• Cancer metastasis to the bone: Mechanisms and animal models (Review)

  2025cites this paper
• Molecular landscape of prostate cancer bone metastasis.

  2024cites this paper
• Construction of a 5-Gene super-enhancer-related signature for osteosarcoma prognosis and the regulatory role of TNFRSF11B in osteosarcoma

  2024cites this paper
• Cell Membrane‐Camouflaged Chitosan‐Polypyrrole Nanogels Co‐Deliver Drug and Gene for Targeted Chemotherapy and Bone Metastasis Inhibition of Prostate Cancer

  2024cites this paper
• Using machine learning approach for screening metastatic biomarkers in colorectal cancer and predictive modeling with experimental validation

  2023cites this paper
• The roles of osteoprotegerin in cancer, far beyond a bone player

  2022cites this paper
• The Risk of the Development and Relationship of Kidney Stone Disease and Osteoporosis (Literature review)

  2022cites this paper
• Molecular mechanisms of osteotropic cancer metastasis (literature review)

  2021cites this paper
• Reduced Serum sRANKL and sTREM2 Levels in High-Grade Gliomas: Association with Prognosis.

  2021cites this paper
• Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis

  2020cites this paper
• Association of Genetic Polymorphisms in TNFRSF11 with the Progression of Genetic Susceptibility to Gastric Cancer

  2020cites this paper
• Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression

  2020cites this paper
• Implication of Prophetic Variables and Their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis.

  2020cites this paper
• Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis

  2020cites this paper
• The Non-Bone-Related Role of RANK/RANKL Signaling in Cancer.

  2020cites this paper
• RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.

  2019cites this paper
• RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review

  2019cites this paper
• The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases

  2018cites this paper
• Identifying metastatic biomarkers of colorectal cancer: Machine learning modeling and experimental validation

  year unknowncites this paper